Who Paid My Doc
Taha Anwar
Surgery Davenport, IA Medical Doctor
NPI 1659721074 CMS profile 1837226
3319 Spring St, Davenport, IA 52807
General payments
$2,101
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Taha Anwar of Davenport, IA is reported in the CMS Open Payments database as having received $2,101 across 33 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 54th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $76 | 4 | |
| 2023 | General | $60 | 3 | |
| 2022 | General | $1,129 | 12 | |
| 2021 | General | $273 | 5 | |
| 2020 | General | $71 | 1 | |
| 2019 | General | $492 | 8 |
Beside peers
- Taha Anwar
- Surgery median
- Middle half of Surgery
- National median
In program year 2025, general payments to Taha Anwar were reported at $0. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.
Show as a table
| Year | Taha Anwar | Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $492 | $253 | $82–$1,521 | $163 |
| 2020 | $71 | $131 | $40–$706 | $114 |
| 2021 | $273 | $168 | $50–$904 | $132 |
| 2022 | $1,129 | $224 | $76–$1,218 | $149 |
| 2023 | $60 | $253 | $82–$1,255 | $160 |
| 2024 | $76 | $279 | $90–$1,381 | $164 |
| 2025 | $0 | $280 | $91–$1,259 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 25 drugsPart D claims
1,313
Drug cost
$170,688
Branded share of claims
33.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gemtesa Vibegron | Brand | 82 | $61,051 | |
| Myrbetriq Mirabegron | Brand | 70 | $54,543 | |
| Orgovyx Relugolix | Brand | 11 | $30,415 | |
| Estradiol | Generic | 100 | $6,880 | |
| Tamsulosin Hcl | Generic | 416 | $5,227 | |
| Potassium Citrate Er Potassium Citrate | Brand | 31 | $4,357 | |
| Trospium Chloride | Generic | 28 | $1,939 | |
| Methenamine Hippurate | Generic | 25 | $1,917 | |
| Finasteride | Generic | 134 | $1,068 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 47 | $646 |
The 10 drugs with the highest cost, of 25 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 107 billing codesPaid by Medicare
$413,823
Medicare patients
649
Services billed
17,784
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 46% | |
| Ischemic heart disease | 34% | |
| Diabetes | 33% | |
| Chronic kidney disease | 31% | |
| Cancer | 24% | |
| Atrial fibrillation | 22% | |
| Depression | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Bcg live intravesical instillation, 1 mg J9030 | Office | 18 | 2,468 | $5,443 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 73 | 9,190 | $950 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 14 | 56 | $16 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
33 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgery in Iowa
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.